Loading clinical trials...
Loading clinical trials...
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma Subjects
This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in childhood patients with B-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.
Age
1 - 18 years
Sex
ALL
Healthy Volunteers
No
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Start Date
November 1, 2016
Primary Completion Date
May 30, 2021
Completion Date
December 30, 2021
Last Updated
February 4, 2021
20
ESTIMATED participants
BinD19
BIOLOGICAL
Lead Sponsor
Shenzhen BinDeBio Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions